Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.

Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention concerns new tumor necrosis factor receptor associated factors, designated TRAF. The new factors are capable of specific association with the intracellular domain of the type 2 TNF receptor (TNF-R2), and are involved in the mediation of TNF biological activities.

Abstract: The present invention related to a method and therapeutic composition for the treatment of coagulation disorders comprising administration of a lipoprotein associated coagulation inhibitor.

Abstract: The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF antibodies of the present invention are designed to comprise a region binding to an epitope in the C-terminal macromolecular substrate binding region of TF.

Abstract: The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating Generalized Anxiety Disorder. The present invention further relates to methods and compositions for treating and preventing symptoms associated with Generalized Anxiety Disorder using a very low dose of cyclobenzaprine.

Abstract: The present invention relates to nucleic acid molecules encoding enzymes which are involved in the starch synthesis in plants. These enzymes are starch synthases from wheat. The invention further relates to vectors and host cells containing said nucleic acid molecules, in particular transformed plant cells and plants regenerated from these cells, which exhibit an increased or a reduced activity of the described starch synthases.

Abstract: Nucleic acid molecules are described encoding enzymes involved in the starch synthesis in plants. These enzymes are a novel isotype of soluble starch synthesis from maize. Furthermore, the invention relates to vectors containing such nucleic acid molecules and to host cells, which have been transformed with the nucleic acid molecules, in particular to transformed plant cells or plants regenerable therefrom, which exhibit an increased or reduced activity of the described proteins.

Abstract: The invention relates to DNA sequences coding for proteins having the enzymatic activity of an amylosucrase which allows the synthesis of linear &agr;-1,4 glucans from the substrate sucrose by bacteria, fungi and plants or in cell-free systems. The invention furthermore describes plasmids and bacteria containing these DNA sequences as well as processes for the production of plants and microorganisms capable of intracellularly or extracellularly expressing a polypeptide having amylosucrase activity. The invention furthermore relates to the production of pure fructose using proteins exhibiting the enzymatic activity of amylosucrase.

Abstract: A process for producing a halogen-containing phosphate ester includes the steps of: (i) reacting a phosphorus halide selected from the group consisting of phosphorus oxyhalides and phosphorus pentahalides with a halogen-containing hydroxy compound to obtain a reaction mixture including a halogen-containing phosphate ester, (ii) purifying the halogen-containing phosphate ester by adding an aqueous medium selected from the group consisting of water, neutral aqueous solutions, acidic aqueous solutions and basic aqueous solutions to the reaction mixture to crystallize the halogen-containing phosphate ester, and (iii) distilling waste water from the purification step.

Abstract: DNA molecules are described which code for a plastid 2-oxoglutarate/malate translocator, particularly from Spinacia oleracea, as well as bacteria, fungi, transgenic plant cells and transgenic plants containing such DNA molecules.